You can see here from the FDA briefing document (https://www.fda.gov/media/140988/download) that the mechanism of action can be used to satisfy the potency requirement for product approval. In the absence of MOA, clinical efficacy can be used as per the FDA briefing documents.
Cell Therapy News/Articles, page-6616
-
- There are more pages in this discussion • 11,414 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
-0.065(6.10%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | 99.5¢ | $2.634M | 2.597M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2794 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 35120 | 21 |
View Market Depth
| Last trade - 13.57pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |